NO980905D0 - Antagonister av den oncogeniske aktivitet av proteinet mdm2 samt anvendelsen derav ved behandling av cancer - Google Patents

Antagonister av den oncogeniske aktivitet av proteinet mdm2 samt anvendelsen derav ved behandling av cancer

Info

Publication number
NO980905D0
NO980905D0 NO980905A NO980905A NO980905D0 NO 980905 D0 NO980905 D0 NO 980905D0 NO 980905 A NO980905 A NO 980905A NO 980905 A NO980905 A NO 980905A NO 980905 D0 NO980905 D0 NO 980905D0
Authority
NO
Norway
Prior art keywords
treatment
oncogenic activity
antagonists
cancer
protein mdm2
Prior art date
Application number
NO980905A
Other languages
English (en)
Other versions
NO319160B1 (no
NO980905L (no
Inventor
Bruno Tocque
Marie Christin Dubs-Poterszman
Bohdan Wasylyk
Original Assignee
Rhone Poulenc Rorer Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med filed Critical Rhone Poulenc Rorer Sa
Publication of NO980905L publication Critical patent/NO980905L/no
Publication of NO980905D0 publication Critical patent/NO980905D0/no
Publication of NO319160B1 publication Critical patent/NO319160B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19980905A 1995-09-04 1998-03-02 Anvendelse av forbindelser som kan antagonisere den oncogeniske aktivitet av proteinet mdm2, anvendelse av en nukleinsyre som koder for slike forbindelser, en viral vektor, et farmasoytisk preparat, samt anvendelse av en nukleinsyresekvens som koder for intracellulaere antistoffer. NO319160B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9510331A FR2738151B1 (fr) 1995-09-04 1995-09-04 Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
PCT/FR1996/001340 WO1997009343A2 (fr) 1995-09-04 1996-09-02 Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers

Publications (3)

Publication Number Publication Date
NO980905L NO980905L (no) 1998-03-02
NO980905D0 true NO980905D0 (no) 1998-03-02
NO319160B1 NO319160B1 (no) 2005-06-27

Family

ID=9482234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19980905A NO319160B1 (no) 1995-09-04 1998-03-02 Anvendelse av forbindelser som kan antagonisere den oncogeniske aktivitet av proteinet mdm2, anvendelse av en nukleinsyre som koder for slike forbindelser, en viral vektor, et farmasoytisk preparat, samt anvendelse av en nukleinsyresekvens som koder for intracellulaere antistoffer.

Country Status (20)

Country Link
US (4) US20030060432A1 (no)
EP (1) EP0848720B1 (no)
JP (2) JPH11511980A (no)
KR (1) KR100592916B1 (no)
AT (1) ATE257711T1 (no)
AU (1) AU722782B2 (no)
BR (1) BR9610386A (no)
CA (1) CA2228667C (no)
CZ (1) CZ298806B6 (no)
DE (1) DE69631335T2 (no)
DK (1) DK0848720T3 (no)
ES (1) ES2210386T3 (no)
FR (1) FR2738151B1 (no)
HU (1) HU223597B1 (no)
IL (1) IL123514A (no)
NO (1) NO319160B1 (no)
PT (1) PT848720E (no)
SK (1) SK287127B6 (no)
WO (1) WO1997009343A2 (no)
ZA (1) ZA967451B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620028D0 (en) * 1996-09-26 1996-11-13 Ludwig Inst Cancer Res Factors which interact with oncoproteins
US6013786A (en) * 1997-08-22 2000-01-11 Hybridon, Inc. MDM2-specific antisense oligonucleotides
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
EP0947494A1 (en) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
DE10109813A1 (de) * 2001-03-01 2002-09-12 Thomas Stanislawski Tumor-Peptidantigen aus humanem mdm2 Proto-Onkogen
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
KR20160061439A (ko) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US20090018078A1 (en) * 2007-07-09 2009-01-15 Vinod Labhasetwar Apoptosis-Modulating Protein Therapy for Proliferative Disorders and Nanoparticles Containing the Same
WO2011098262A2 (en) 2010-02-09 2011-08-18 Universität Bremen P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
CN107216380A (zh) 2012-02-15 2017-09-29 爱勒让治疗公司 拟肽大环化合物
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
WO2015084897A2 (en) 2013-12-02 2015-06-11 Mirimmune, Llc Immunotherapy of cancer
WO2015168108A2 (en) * 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
CN111491661A (zh) * 2017-07-27 2020-08-04 诺莫坎制药有限责任公司 M(h)dm2/4的抗体及其在诊断和治疗癌症中的用途
WO2020159504A1 (en) * 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
EP0654092B1 (en) * 1992-06-26 2003-09-10 The Trustees Of Princeton University Method for detecting pre-cancerous or cancerous cells using p90 and p53 antibodies or probes
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
US5770377A (en) * 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof

Also Published As

Publication number Publication date
US20080311608A1 (en) 2008-12-18
US20030060432A1 (en) 2003-03-27
EP0848720A2 (fr) 1998-06-24
HU223597B1 (hu) 2004-10-28
FR2738151B1 (fr) 1997-09-26
KR100592916B1 (ko) 2006-11-07
US20040209834A1 (en) 2004-10-21
FR2738151A1 (fr) 1997-03-07
ATE257711T1 (de) 2004-01-15
CA2228667C (fr) 2013-06-04
WO1997009343A3 (fr) 1997-05-29
IL123514A (en) 2006-10-31
CZ298806B6 (cs) 2008-02-06
CA2228667A1 (fr) 1997-03-13
BR9610386A (pt) 1999-10-13
JP2011225571A (ja) 2011-11-10
JPH11511980A (ja) 1999-10-19
SK28098A3 (en) 1998-08-05
DK0848720T3 (da) 2004-04-19
HUP9900406A2 (hu) 1999-05-28
AU722782B2 (en) 2000-08-10
MX9801407A (es) 1998-05-31
ES2210386T3 (es) 2004-07-01
EP0848720B1 (fr) 2004-01-14
IL123514A0 (en) 1998-10-30
AU6933496A (en) 1997-03-27
DE69631335D1 (de) 2004-02-19
CZ63098A3 (cs) 1998-06-17
NO319160B1 (no) 2005-06-27
KR19990044356A (ko) 1999-06-25
NO980905L (no) 1998-03-02
HUP9900406A3 (en) 2002-04-29
DE69631335T2 (de) 2004-12-02
WO1997009343A2 (fr) 1997-03-13
PT848720E (pt) 2004-05-31
ZA967451B (en) 1997-03-10
SK287127B6 (sk) 2009-12-07
US20140030319A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
NO980905D0 (no) Antagonister av den oncogeniske aktivitet av proteinet mdm2 samt anvendelsen derav ved behandling av cancer
MXPA02011303A (es) Nueva composicion farmaceutica.
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
HUP0001136A2 (hu) Limfatikus tumorok kezelésére szolgáló gyógyszerkészítmények
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
SE9704546D0 (sv) Novel compounds
DE69830751D1 (de) Polyaromatische Verbindungen zur Behandlung von Herpes-Infektionen
CA2200195A1 (en) Use of aromatase inhibitors for the production of a pharmaceutical agentfor treating a relative androgen deficiency in men
AUPP589598A0 (en) Novel peptides
HUP0204449A3 (en) Oncolytic combinations for the treatment of cancer, containing 2',2'-difluoronucleoside and leukotriene antagonist as active ingredients
AU4363199A (en) Use of hmg proteins for the preparation of medicaments having cytotoxic activity
CA2155017A1 (en) Vpr function and activity
MX9703364A (es) Peptidos capaces de unirse al dominio sh3 de la proteina gap, secuencias nucleotidicas que codifican para estos peptidos, su preparacion y su uso.
AU1031697A (en) Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
PT1024809E (pt) Utilizacao de agentes de imunomodulacao
TR200101366T2 (tr) Farmasötik kompozisyonların muhtevasında bulunan bazı substitüte kaprolaktamlar ve tümör tedavisinde kullanımları.
GR3035710T3 (en) Substituted benzenesulfonylureas and -thioureas, process for their preparation and the use of pharmaceutical preparations based on these compounds as well as medicaments containing them
DE69733026D1 (de) Cyclin e spezifische konstrukte und komplexe
WO2000006735A8 (en) Interferon alpha hybrids
CA2177600A1 (fr) Sequences d'acides nucleiques regulatrices et utilisations
DE59813114D1 (de) BK-RiV-Präparate zur Behandlung von proliferativen Zellerkrangungen
AU1275095A (en) Antiviral composition of viral protein trans-dominant variants
WO2001011335A3 (en) Antiviral compounds that inhibit viral replication
MX9701865A (es) Compuestos de dimetil-(3-aril-but-3-enil)-amino como ingredientes activos farmaceuticos.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees